Lymphoma, B-Cell: all 1,415 studies
Page 1 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT07888530
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingNCT07883135Phase 2
- RPM Signals in Outpatient CAR T TherapyNot yet recruitingNCT07882732
- A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell LymphomaNot yet recruitingNCT07882576
- Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)Not yet recruitingNCT07871747Phase 1
- Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaRecruitingNCT07862010Early Phase 1
- Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple MyelomaNot yet recruitingNCT07852377Not applicable
- In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell LymphomaRecruitingNCT07775508Phase 1
- BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple MyelomaNot yet recruitingNCT07771361Phase 2
- Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical PracticeNot yet recruitingNCT07767799
- Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell LymphomaNot yet recruitingNCT07754682Phase 3
- Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.RecruitingNCT07739654Phase 3
- A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesRecruitingNCT07735533Phase 1/2
- INfections in Patients Treated With CAR-TNot yet recruitingNCT07713511
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingNCT07711483Phase 2
- Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNot yet recruitingNCT07695896
- A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 1
- A Clinical Study of SHR-3079 in B-cell Non-Hodgkin LymphomaRecruitingNCT07661537Phase 1
- A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNot yet recruitingNCT07658352Phase 1/2
- Toxin Exposure and Immune Dysregulation in Non-Hodgkin LymphomaRecruitingNCT07652580
- Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell LymphomaNot yet recruitingNCT07622784Phase 2
- Phase I Study of FXS0683 in the Treatment of Blood TumorsRecruitingNCT07616089Phase 1
- A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin LymphomaRecruitingNCT07609030Not applicable
- Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.RecruitingNCT07593482Phase 2
- Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaNot yet recruitingNCT07588698Phase 2
- Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic MalignanciesRecruitingNCT07584889Phase 1/2
- Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT07584850Early Phase 1
- Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCLNot yet recruitingNCT07569965Phase 2
- RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell LymphomasNot yet recruitingNCT07563543Early Phase 1
- A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin LymphomaRecruitingNCT07548697Early Phase 1
- Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell LymphomaNot yet recruitingNCT07546630Early Phase 1
- Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell LymphomaNot yet recruitingNCT07539688Phase 1
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaRecruitingNCT07532525Phase 1
- Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Phase 1/2
- Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesRecruitingNCT07520006Phase 1/2
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLRecruitingNCT07516093Phase 3
- Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell LymphomaRecruitingNCT07508605Phase 1/2
- RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell LymphomasNot yet recruitingNCT07506668Phase 1/2
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingNCT07502872Phase 2
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruitingNCT07477366Phase 2
- Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsEnrolling by invitationNCT07474051
- CD45BE-HSPC + CART-45 CellsRecruitingNCT07451054Phase 1
- A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's LymphomaRecruitingNCT07439653Phase 1/2
- Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell LymphomaRecruitingNCT07398963Phase 1
- Research for Resistance Factors in the Treatment of Lymphoid HemopathyNot yet recruitingNCT07385612
- A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT07376642Early Phase 1
- Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell LymphomaRecruitingNCT07369492Phase 1
- Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell LymphomaNot yet recruitingNCT07367685Phase 1
- Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT07345741Not applicable
- Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell MalignanciesNot yet recruitingNCT07335328Phase 1
- Clinical Study of XP-006 mRNA Vaccine for R/R B-NHLNot yet recruitingNCT07334574Phase 1
- Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell LymphomasRecruitingNCT07319676Phase 1/2
- A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell LymphomasNot yet recruitingNCT07316920Phase 1
- Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT07283679Phase 1/2
- Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaRecruitingNCT07270835Phase 4
- In VIVO CAR-T Therapy for Relapsed/Refractory Hematological MalignanciesRecruitingNCT07239323Phase 1
- A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell NeoplasmsNot yet recruitingNCT07234045Phase 1
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
- A First-in-Human Trial of DS3790a in Participants With Hematological MalignanciesRecruitingNCT07220616Phase 1/2
- Anti CD19 Gene Therapy for B-cell LymphomaRecruitingNCT07211048Not applicable
- A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic AnemiaRecruitingNCT07205315Early Phase 1
- Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell LymphomaNot yet recruitingNCT07198373
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyRecruitingNCT07188558Phase 3
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasEnrolling by invitationNCT07168486Phase 1
- Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell LymphomaNot yet recruitingNCT07168291Early Phase 1
- Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)Not yet recruitingNCT07166549Phase 1
- This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.Enrolling by invitationNCT07162571Phase 1/2
- Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaRecruitingNCT07125872Phase 2
- A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT07123454Phase 1/2
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )RecruitingNCT07101328Phase 1
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT07097363Phase 2
- Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell LymphomaRecruitingNCT07097207Phase 1/2
- Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaRecruitingNCT07093073Phase 1
- Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingNCT07077512Phase 2
- The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin LymphomaRecruitingNCT07073833Phase 1
- A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)RecruitingNCT07072169Phase 1
- A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT07068906Phase 1
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )RecruitingNCT07053670Phase 1
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )Not yet recruitingNCT07032324Phase 1
- JWCAR239 in Patients With B Cell Non-Hodgkin LymphomaNot yet recruitingNCT07024147Phase 1
- BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell LymphomaRecruitingNCT07009002Phase 1/2
- Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous TransplantationRecruitingNCT07001540Phase 2
- Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaRecruitingNCT06996132Phase 2
- Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell LymphomaRecruitingNCT06987916Phase 1/2
- A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsRecruitingNCT06976437Early Phase 1
- A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.Not yet recruitingNCT06970496Phase 1
- Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell LymphomaRecruitingNCT06961669Not applicable
- Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell LymphomaNot yet recruitingNCT06956092Phase 4
- Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)RecruitingNCT06954805Phase 2
- Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell LymphomaNot yet recruitingNCT06935136Not applicable
- Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy FailureRecruitingNCT06918912Phase 2
- The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic TumorsRecruitingNCT06911710Phase 1/2
- A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell MalignanciesNot yet recruitingNCT06894693Phase 1
- Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular SubtypesRecruitingNCT06891157Phase 2
- Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCLNot yet recruitingNCT06890585Phase 2
- Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell MalignanciesRecruitingNCT06879340Phase 1
- Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell LymphomaEnrolling by invitationNCT06871007Phase 1/2
- CD-19 CAR-T Cell for Pediatric ALL or LymphomaRecruitingNCT06866873Not applicable
- CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory LymphomaRecruitingNCT06850285Not applicable
- Systemic Inflammatory Markers in B-cell NeoplasmNot yet recruitingNCT06847529